Today: 24 January 2026
Subscribe
Browse Category

NASDAQ:NVO News 12 January 2026 - 18 January 2026

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

New York, January 18, 2026, 10:06 EST — Market closed Eli Lilly shares ended Friday at $1,038.40, rising 0.5% after fluctuating between $1,019 and $1,049.83 during the session. With U.S. markets shut for the weekend, traders are left to digest regulatory and competitive developments ahead of Monday’s open. Why it matters now: Lilly’s next valuation boost hinges on weight loss,…
18 January 2026
······
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

New York, Jan 12, 2026, 10:58 EST — Regular session Eli Lilly’s stock climbed in early trading Monday following the announcement that the drugmaker and Nvidia plan to invest roughly $1 billion over five years in a joint research lab focused on accelerating drug discovery. The news comes as executives and investors gather at the J.P. Morgan Healthcare Conference in…
12 January 2026
·······

Stock Market Today

  • TransAlta (TSX:TA) Valuation Reviewed Amid Share Price Decline
    January 23, 2026, 11:41 PM EST. TransAlta (TSX:TA) has seen its share price fall nearly 28% over 90 days, currently trading at CA$17.41, prompting fresh valuation scrutiny. Despite short-term weakness, a five-year total shareholder return of 69.31% highlights longer-term gains. Analysts estimate a fair value of approximately CA$24.27 based on future cash flow growth linked to renewable energy projects and asset optimization. The stock trades at 2.1 times sales, exceeding a fair 1.0 times benchmark but below sector peers, raising questions about growth justification. Risks include potential disruptions in data center contracts and carbon pricing changes. Investors are weighing the under-valuation signal against the premium sales ratio amid evolving market conditions.
Go toTop